Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13641018 | 0.89 | OPRM1 (0.42) | OPRM1OPRL1OPRK1TNKSTNKS2 | |
| SCHEMBL12084460 | 0.88 | OPRM1 (0.47) | OPRM1OPRL1OPRK1TNKSTNKS2 | |
| SCHEMBL13001313 | 0.88 | OPRM1 (0.47) | OPRM1OPRL1OPRK1TNKSTNKS2 | |
| SCHEMBL13641003 | 0.87 | MEN1 (0.40) | OPRM1OPRL1OPRK1TNKSTNKS2 | |
| SCHEMBL13640925 | 0.84 | TNKS (0.42) | OPRM1OPRL1OPRK1TNKSTNKS2 | |
| SCHEMBL14467572 | 0.83 | OPRM1 (0.43) | OPRM1OPRL1OPRK1TNKSTNKS2 | |
| SCHEMBL14467604 | 0.82 | OPRM1 (0.46) | OPRM1OPRL1OPRK1TNKSTNKS2 | |
| SCHEMBL12084873 | 0.82 | OPRM1 (0.43) | OPRM1OPRL1OPRK1TNKSTNKS2 | |
| SCHEMBL13640761 | 0.82 | OPRM1 (0.45) | OPRM1OPRL1OPRK1TNKSTNKS2 | |
| SCHEMBL12084407 | 0.81 | OPRM1 (0.47) | OPRM1OPRL1OPRK1TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | OPRM1 177/4885OPRL1 108/4885OPRK1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.